Colorectal Cancer Update
Live Clinical Investigator Think Tank:
Proceedings from a CME Satellite Meeting at the Gastrointestinal Cancers Symposium in Orlando, Florida

EDITOR AND MODERATOR
Neil Love, MD

FACULTY
Richard M Goldberg, MD
Axel Grothey, MD
Daniel G Haller, MD
Howard S Hochster, MD
Neal J Meropol, MD
Michael J O’Connell, MD
Alan P Venook, MD

from the publishers of
Colorectal Cancer™ Update

Subscribe to Podcasts or download MP3s of this program at ColorectalCancerUpdate.com/LiveThinkTank
**STATEMENT OF NEED/TARGET AUDIENCE**

Colorectal cancer is among the most common types of cancer in the United States, and the arena of colorectal cancer treatment continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic agents and regimens and changes in the indications, doses and schedules for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists in the formulation of up-to-date clinical management strategies.

**LEARNING OBJECTIVES**

- Select medical and surgical treatment regimens for patients with colorectal cancer, based on key clinical and pathological risk factors.
- Develop an evidence-based algorithm for the initial treatment for localized Stage II and Stage III colon cancer, in the context of the risks and benefits of adjuvant systemic therapy.
- Assess emerging clinical research information and ongoing trials to decide on the value of continuing molecular-targeted therapy beyond disease progression.
- Evaluate existing data and emerging research on the optimal management of locally advanced rectal cancer, including pre- and postoperative concomitant chemoradiation therapy and additional adjuvant systemic therapy, and incorporate relevant information into management strategies.
- Review the multiple sequential treatment approaches for recurrent or de novo advanced colorectal cancer:
  - Describe the benefits and risks of single-agent and combination chemotherapy regimens.
  - Critically evaluate the current data integrating VEGF and/or EGFR-inhibiting agents into the treatment algorithm.
- Discuss the risks and benefits of neoadjuvant or adjuvant systemic therapy for colorectal cancer with appropriate patients with potentially curable hepatic metastases.
- Counsel appropriately selected patients about clinical trial participation.

**PURPOSE OF THIS ISSUE**

The purpose of this program is to support the learning objectives by offering the perspectives of Drs Goldberg, Grothey, Haller, Hochster, Meropol, O’Connell and Venook on the integration of emerging clinical research data into the management of colorectal cancer.

**ACCREDITATION STATEMENT**

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**CREDIT DESIGNATION STATEMENT**

Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**HOW TO USE THIS CME ACTIVITY**

This CME activity contains an audio component. To receive credit, the participant should listen to the CD, review the CME information and complete the Post-test and Educational Assessment and Credit Form located in the back of this book or on our website, ColorectalCancerUpdate.com/LiveThinkTank.

*This program is supported by educational grants from Genentech BioOncology and Sanofi-Aventis.*
If you would like to discontinue your complimentary subscription to Colorectal Cancer Update, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

EDITOR AND MODERATOR
Neil Love, MD
Medical Oncologist
Editor, Colorectal Cancer Update
Research To Practice
Miami, Florida

FACULTY AFFILIATIONS
Richard M Goldberg, MD
Professor and Chief
Division of Hematology/Oncology
Associate Director
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Daniel G Haller, MD
Professor of Medicine
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania

Howard S Hochster, MD
Professor of Medicine and Clinical Pharmacology
New York, New York

Neil J Meropol, MD
Director
Gastrointestinal Cancer Program
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Michael J O'Connell, MD
Associate Chairman
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Pittsburgh, Pennsylvania

Alan P Venook, MD
Professor of Clinical Medicine
University of California
San Francisco

CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: 


RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
POST-TEST

**Colorectal Cancer Update Live Clinical Investigator Think Tank:**
*Proceedings from a CME Satellite Meeting at the Gastrointestinal Cancers Symposium in Orlando, Florida*

**QUESTIONS (PLEASE CIRCLE ANSWER):**

1. The OPTIMOX2 study evaluated chemotherapy-free intervals versus maintenance therapy with ________ for patients with mCRC treated with FOLFOX.
   a. Oxaliplatin
   b. Irinotecan
   c. Bevacizumab
   d. 5-FU/leucovorin

2. Findings from the 20,800-patient ACCENT data set indicate that patients with Stage III colon cancer have a longer survival after recurrence than patients with Stage II colon cancer.
   a. True
   b. False

3. In the preliminary safety data from NSABP-C-08, the addition of bevacizumab to adjuvant FOLFOX resulted in a significant increase in ________.
   a. Gastrointestinal perforation
   b. Stroke
   c. Congestive heart failure
   d. None of the above

4. Data indicate that patients with K-ras mutations consistently benefit from anti-EGFR antibody therapies, such as cetuximab and panitumumab.
   a. True
   b. False

5. In the BRiTE observational study of patients who received first-line bevacizumab-containing chemotherapy, no improvement occurred in overall survival for patients who continued to receive bevacizumab beyond disease progression.
   a. True
   b. False

6. The iBET randomized trial (SWOG-S0600) is evaluating the hypothesis that continuation of bevacizumab beyond disease progression is associated with improvement in overall survival.
   a. True
   b. False

7. CALGB-C80405 is evaluating ________ with FOLFOX or FOLFIRI for patients with previously untreated mCRC.
   a. Cetuximab
   b. Bevacizumab
   c. Cetuximab and bevacizumab
   d. All of the above

8. In the QUASAR adjuvant study, an improvement in overall survival was evident among patients with Stage II colon cancer who received ________ compared to observation.
   a. FOLFOX
   b. FOLFIRI
   c. Capecitabine
   d. 5-FU

9. ECOG is conducting a Phase III randomized trial in rectal cancer evaluating ________ for patients who have undergone neoadjuvant chemoradiation therapy and surgery.
   a. Capecitabine with or without oxaliplatin
   b. FOLFOX with or without cetuximab
   c. FOLFOX with or without bevacizumab

10. RTOG-0247 is a randomized Phase II trial evaluating ________ for patients with locally advanced rectal cancer undergoing surgical resection.
    a. Preoperative FOLFOX
    b. Preoperative radiation therapy and FOLFOX
    c. Preoperative radiation therapy and capecitabine with or without oxaliplatin followed by adjuvant FOLFOX

*Post-test answer key: 1d, 2b, 3d, 4b, 5b, 6a, 7d, 8d, 9c, 10c*
EDUCATIONAL ASSESSMENT AND CREDIT FORM

Colorectal Cancer Update Live Clinical Investigator Think Tank: Proceedings from a CME Satellite Meeting at the Gastrointestinal Cancers Symposium in Orlando, Florida

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART ONE — Please tell us about your experience with this educational activity

BEFORE completion of this activity, how would you characterize your level of knowledge on the following topics?

4 = Expert 3 = Above average 2 = Competent 1 = Insufficient

Potential benefits of adjuvant systemic therapy for patients with Stage II disease .................. 4 3 2 1
K-ras mutations and response to anti-EGFR antibody therapies .................. 4 3 2 1
Continuation of bevacizumab upon disease progression .................. 4 3 2 1
Systemic therapy for patients with potentially curable hepatic metastases .................. 4 3 2 1

AFTER completion of this activity, how would you characterize your level of knowledge on the following topics?

4 = Expert 3 = Above average 2 = Competent 1 = Insufficient

Potential benefits of adjuvant systemic therapy for patients with Stage II disease .................. 4 3 2 1
K-ras mutations and response to anti-EGFR antibody therapies .................. 4 3 2 1
Continuation of bevacizumab upon disease progression .................. 4 3 2 1
Systemic therapy for patients with potentially curable hepatic metastases .................. 4 3 2 1

Was the activity evidence based, fair, balanced and free from commercial bias?

☐ Yes ☐ No
If no, please explain:

Will this activity help you improve patient care?

☐ Yes ☐ No ☐ Not applicable
If no, please explain:

Did the activity meet your educational needs and expectations?

☐ Yes ☐ No
If no, please explain:

Please respond to the following LEARNER statements by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = Learning objective not met N/A = Not applicable

As a result of this activity, I will:

• Select medical and surgical treatment regimens for patients with colorectal cancer, based on key clinical and pathological risk factors. .................. 4 3 2 1 N/M N/A

• Develop an evidence-based algorithm for the initial treatment for localized Stage II and Stage III colon cancer, in the context of the risks and benefits of adjuvant systemic therapy. .................. 4 3 2 1 N/M N/A

• Assess emerging clinical research information and ongoing trials to decide on the value of continuing molecular-targeted therapy beyond disease progression. .................. 4 3 2 1 N/M N/A

• Evaluate existing data and emerging research on the optimal management of locally advanced rectal cancer, including pre- and postoperative concomitant chemoradiation therapy and additional adjuvant systemic therapy, and incorporate relevant information into management strategies. .................. 4 3 2 1 N/M N/A

• Review the multiple sequential treatment approaches for recurrent or de novo advanced colorectal cancer:
  – Describe the benefits and risks of single-agent and combination chemotherapy regimens. .................. 4 3 2 1 N/M N/A
  – Critically evaluate the current data integrating VEGF and/or EGFR-inhibiting agents into the treatment algorithm. .................. 4 3 2 1 N/M N/A

• Discuss the risks and benefits of neoadjuvant or adjuvant systemic therapy for colorectal cancer with appropriate patients with potentially curable hepatic metastases. .................. 4 3 2 1 N/M N/A

• Counsel appropriately selected patients about clinical trial participation. .................. 4 3 2 1 N/M N/A
EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

What other practice changes will you make or consider making as a result of this activity?

What additional information or training do you need on the activity topics or other oncology-related topics?

Additional comments about this activity:

May we include you in future assessments to evaluate the effectiveness of this activity?

☐ Yes  ☐ No

PART TWO — Please tell us about the faculty for this educational activity

<table>
<thead>
<tr>
<th>Faculty</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard M Goldberg, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Axel Grothey, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Daniel G Haller, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Howard S Hochster, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Neal J Meropol, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Michael J O’Connell, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Alan P Venook, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Please recommend additional faculty for future activities:

Other comments about the faculty for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: .................................................. Specialty: ..................................
Degree: ☐ MD  ☐ DO  ☐ PharmD  ☐ NP  ☐ BS  ☐ RN  ☐ PA  ☐ Other ............
Medical License/ME Number: ................................................................. Last 4 Digits of SSN (required): ..................................
Street Address: ................................................................. Box/Suite: ..................................
City, State, Zip: .......................................... Telephone: ................................ Fax: ..................................
Email: .................................................................

Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _________ hour(s).

Signature: ................................................................. Date: ..................................

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ColorectalCancerUpdate.com/LiveThinkTank/CME.